A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Theranostics is the combination of two approaches—diagnostics and therapeutics—applied for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of theranostics has increased in recent years, with U.S. Food and Drug Administration (FDA) approval of lutetium 177 (177Lu) tetraazacyclododecane tetraacetic acid octreotate (DOTATATE) and 177Lu–prostate-specific membrane antigen vector-based radionuclide therapies. The field of theranostics has imminent potential for emerging clinical applications. This article reviews critical areas of active clinical advancement in theranostics, including forthcoming clinical trials advancing FDA-approved and emerging radiopharmaceuticals, approaches to dosimetry calculations, imaging of different radionuclide therapies, expanded indications for currently used theranostic agents to treat a broader array of cancers, and emerging ideas in the field. Keywords: Molecular Imaging, Molecular Imaging–Cancer, Molecular Imaging–Clinical Translation, Molecular Imaging–Target Development, PET/CT, SPECT/CT, Radionuclide Therapy, Dosimetry, Oncology, Radiobiology © RSNA, 2023
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236414 · Cited by 292
Somatostatin receptor antagonists for imaging and therapy.
Fani, M., Nicolas, G. P., & Wild, D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186783 · Cited by 274
Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3945-z · Cited by 254
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215
Research works printed but not linked: 87
- 10.1038/s41598-019-54884-7 · DOI
- 10.2214/AJR.19.21123 · DOI
- Modoni S, 2021, Q J Nucl Med Mol Imaging, 65, 299
- 10.1001/jama.1983.03340150084036 · doi:10.1001/jama.1983.03340150084036
- Kassis AI, 2005, J Nucl Med, 46, 4S
- 10.1001/jamaoncol.2018.4044 · DOI · Paper page
- 10.1186/s13550-014-0038-2 · DOI
- 10.3390/cancers13153676 · DOI
- 10.1186/s41181-019-0075-2 · DOI · Paper page
- 10.1016/S1470-2045(21)00657-4 · DOI
- 10.2967/jnumed.108.053173 · DOI · Paper page
- 10.1056/NEJM198310203091601 · DOI · Paper page
- 10.1089/105072502753522356 · DOI
- 10.1097/CCO.0000000000000691 · DOI
- 10.1007/s00259-017-3678-4 · DOI · Paper page
- 10.2214/AJR.19.22626 · DOI
- 10.1159/000337634 · doi:10.1159/000337634
- 10.1053/j.semnuclmed.2009.11.004 · doi:10.1053/j.semnuclmed.2009.11.004
- 10.1158/1078-0432.CCR-16-2955 · DOI · Paper page
- 10.1148/radiol.2020201745 · DOI
- 10.1016/S1470-2045(21)00572-6 · DOI · Paper page
- Nicolas G, 2015, J Nucl Med, 56, 335
- 10.1111/bju.14876 · DOI · Paper page
- 10.1002/jmrs.227 · DOI · Paper page
- Mullard A, 2022, Nat Rev Drug Discov, 21, 327
- 10.2967/jnumed.116.178673 · DOI · Paper page
- 10.1038/s41391-021-00349-w · DOI
- 10.1016/j.clon.2020.10.020 · DOI
- 10.1016/S0140-6736(89)91258-0 · DOI · Paper page
- 10.1007/s00259-022-06089-w · DOI · Paper page
- 10.2967/jnumed.118.230607 · DOI · Paper page
- 10.1016/j.euo.2022.05.003 · DOI
- 10.2967/jnumed.122.264860 · DOI
- 10.1007/s00259-019-04485-3 · DOI · Paper page
- 10.2967/jnumed.122.264398 · DOI
- 10.3390/diagnostics12020528 · DOI
- 10.1210/jc.2017-00816 · DOI
- 10.3390/jcm8070952 · DOI
- Forrer F, 2008, Q J Nucl Med Mol Imaging, 52, 334
- 10.1007/s12032-016-0737-9 · DOI
- 10.1007/s00259-015-3029-2 · doi:10.1007/s00259-015-3029-2
- van Essen M, 2006, J Nucl Med, 47, 1599
- 10.1055/s-0032-1311637 · doi:10.1055/s-0032-1311637
- 10.6004/jnccn.2018.0056 · DOI · Paper page
- 10.1007/s00259-016-3527-x · DOI
- 10.1158/1078-0432.CCR-20-3703 · DOI
- 10.1007/s00259-009-1115-z · DOI
- Seystahl K, 2016, Neuro-oncol, 18, 1538
- 10.1016/j.mayocpiqo.2020.09.015 · DOI
- Van de Wiele C, 2020, Histol Histopathol, 35, 919
- 10.1007/s00259-021-05433-w · DOI
- 10.1007/s00259-020-04715-z · doi:10.1007/s00259-020-04715-z
- 10.1097/RLU.0000000000003142 · doi:10.1097/rlu.0000000000003142
- 10.4103/wjnm.WJNM_112_18 · doi:10.4103/wjnm.wjnm_112_18
- 10.2967/jnumed.120.257915 · DOI
- 10.2967/jnumed.109.068957 · DOI · Paper page
- 10.1007/s00259-013-2547-z · DOI
- 10.1200/JCO.2022.40.16_suppl.e16212 · doi:10.1200/jco.2022.40.16_suppl.e16212
- 10.1155/2021/6615511 · DOI
- 10.1016/j.ctrv.2020.102141 · DOI
- 10.1056/NEJMoa1209288 · DOI · Paper page
- Freudenberg LS, 2007, Nucl Med (Stuttg), 46, 121
- 10.2967/jnumed.114.148437 · DOI · Paper page
- 10.1007/s00259-017-3688-2 · DOI
- 10.2967/jnumed.115.159012 · DOI · Paper page
- Macapinlac HA, 1996, J Nucl Med, 37, 25S
- 10.1093/annonc/10.suppl_2.S23 · DOI · Paper page
- 10.1053/snuc/2002.31025 · DOI · Paper page
- Vallis KA, 2014, Am J Nucl Med Mol Imaging, 4, 181
- 10.3171/2010.2.JNS091211 · DOI
- 10.1016/j.cpet.2021.03.010 · DOI
- 10.3390/cancers13225766 · DOI
- 10.1007/s00259-019-04504-3 · DOI
- 10.2967/jnumed.116.176636 · DOI
- 10.2967/jnumed.119.227967 · DOI · Paper page
- 10.2967/jnumed.118.210443 · DOI · Paper page
- 10.3389/fonc.2021.758958 · DOI
- 10.1097/RLU.0000000000003810 · DOI · Paper page
- 10.2967/jnumed.120.259192 · DOI · Paper page
- Ferdinandus J, 2022, J Nucl Med, 63, 727
- 10.2967/jnumed.118.224469 · DOI · Paper page
- 10.1007/s00259-020-05023-2 · doi:10.1007/s00259-020-05023-2
- Bal C, 2020, J Nucl Med, 61, 416
- 10.2967/jnumed.122.264456 · DOI
- 10.1159/000434723 · DOI · Paper page
- 10.1530/ERC-21-0082 · doi:10.1530/erc-21-0082
- 10.1200/JCO.2022.40.16_suppl.4122 · doi:10.1200/jco.2022.40.16_suppl.4122
Cited by
Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions
Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083560 · Cited by 1
“Related to these properties, several theranostic drugs have already been approved by the FDA for cancer therapy [35].”
Metadata
- Authors
- Burkett, B. J., Bartlett, D. J., McGarrah, P. W., Lewis, A. R., Johnson, D. R., Berberoğlu, K., Pandey, M. K., Packard, A. T., Halfdanarson, T. R., Hruska, C. B., Johnson, G. B., & Kendi, A. T.
- Venue
- Radiology: Imaging Cancer
- Published
- 2023-07-01
- Volume
- 5
- Issue
- 4
- Pages
- e220157-e220157
- ISSN
- 2638-616X (ISSN-L)
- OpenAlex
- W4384925643
- Cited by
- 217
- References
- 7
- FWCI
- 32.03
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.